1. 科研項目 1) c7c7.app附屬腫瘤醫(yī)院碩導(dǎo)伴飛基金(SD202309), 經(jīng)費(fèi)20萬 2) 山西省衛(wèi)生健康委新冠專項課題(2023XG046),經(jīng)費(fèi)3萬 3) 山西省醫(yī)學(xué)重點(diǎn)科研引導(dǎo)性科技專項(項目編號:2020XM52)10 萬; 2. 學(xué)術(shù)論文 1) Liang SF, Tian X , Wang CY. Nanozymes in the Treatment of Diseases Caused by Excessive Reactive Oxygen Specie. Journal of Inflammation Research 2022,15: 6307-6328. (IF: 4.631通訊作者 ) 2) Wang CY, Guo ST, Croft A, Yan XG, Jin L, Zhang XD, Jiang CC. BAG3-dependent expression of Mcl-1 confers resistance of mutant KRAS colon cancer cells to the HSP90 inhibitor AUY922. Mol Carcinog.2018 Feb; 57(2): 284-294.(IF: 4.185) 3) Wang CY, Guo ST, Wang JY, Liu F, Zhang YY, Yari H, Yan XG, Jin L, Zhang XD, Jiang CC. Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress. Mol Cancer Ther. 2016 Feb 1. [Epub ahead of print](IF: 5.683) 4) Wang CY, Guo ST, Wang JY, Yan XG, Farrelly Ma, Zhang YY, Liu F, Yari H, La T, Lei FX, Jin L, Zhang XD, Jiang CC. Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922。 Oncotarget. 2016 July 06 (IF: 5.008) 3. 學(xué)術(shù)榮譽(yù):無 4. 科技獎勵:山西省科學(xué)技術(shù)進(jìn)步獎二等獎1項,2013 5. 發(fā)明專利:無 6. 學(xué)術(shù)任職 1) 中國醫(yī)學(xué)裝備協(xié)會基因檢測分會委員 2) 山西省臨床檢驗質(zhì)量控制專家委員會委員 3) 山西省抗癌協(xié)會胃癌專業(yè)委員會常務(wù)委員 4) 中國醫(yī)學(xué)裝備協(xié)會數(shù)學(xué)醫(yī)學(xué)裝備技術(shù)委員會委員 5) 山西省腫瘤醫(yī)學(xué)醫(yī)療質(zhì)量控制中心惡行黑色素瘤專委會常務(wù)委員 |